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Introduction {#sec1}
============

Cells in the human body can be broadly classified as two major types, germline and somatic cells. The fusion of fully differentiated germ cells (i.e., sperm and oocyte) produces a totipotent zygote. Since all cells harbor the same genetic code, differentiation depends on the epigenetic state of each cell; germ cells reprogram epigenetic information during their specification, development, and maturation to acquire toti- or pluripotency. Germ cells in mice are specified from proximal epiblast cells that lack expression of some subsets of pluripotency genes such as *Nanog*, Kruppel-like factor 2 (*Klf2*), and T cell leukemia/lymphoma 1 (*Tcl1*), which are regulated by the transcription factors B lymphocyte-induced maturation protein 1 (BLIMP1), PR domain-containing 14 (PRDM14), and transcription factor AP-2 gamma (TFAP2C) ([@bib21], [@bib22], [@bib23], [@bib37], [@bib39], [@bib40]). Specified PGCs reactivate pluripotency-associated genes and can be used to derive embryonic germ cells (EGCs) via stimulation with three cytokines, basic fibroblast growth factor (bFGF), stem cell factor (SCF), and leukemia inhibitory factor (LIF) ([@bib20]). Migrating PGCs in the hindgut replace repressive DNA methylation and H3K9 methylation marks with a repressive H3K27 trimethylation mark in their genome during migration ([@bib31], [@bib32]). DNA demethylation occurs as a two-step process: the first demethylation wave occurs in a genome-wide manner during migration and a second wave occurs in a locus-specific manner, for example at germline-specific genes and imprinted loci at the time when PGCs arrive at the gonads ([@bib30]). CpG methylation marks can be removed via replication-dependent and independent mechanisms ([@bib38]). The former is regulated by inhibition of DNA methyltransferase activity during de novo DNA synthesis, whereas the latter (also known as active demethylation) is triggered by oxidation of 5-methylcytosine catalyzed by ten-eleven translocation (TET) proteins, which is followed by base excision repair (BER) ([@bib8]). PGCs use both active and passive demethylation to erase genome-wide methylation marks ([@bib9], [@bib14], [@bib15], [@bib24], [@bib27]). Global hypomethylation is induced in the transition from metastable embryonic stem cells (ESCs) cultured with serum plus LIF to ground-state ESCs cultured with 2i plus LIF, which is similar to the first wave of DNA demethylation in migratory PGCs ([@bib6]).

We have previously shown that PRDM14 is transiently expressed in the inner cell mass (ICM) of blastocysts at embryonic day 3.5 (E3.5) and reactivated in specifying PGCs at approximately E6.25 ([@bib40]). Knockout (KO) studies have demonstrated that expression of *Prdm14* in the ICM is required for priming of the epiblast cells for proper somatic differentiation ([@bib26]), and that expression of PGCs is critical for establishment of the germline in mice ([@bib40]). Furthermore, induction of PRDM14 in epiblast-like cells (EpiLCs) induced from ESCs is sufficient for PGC-like cell (PGCLC) induction in aggregate culture ([@bib11]). KO and overexpression studies of *Prdm14* suggest that PRDM14 is a critical determinant for PGC specification in mice. However, recent studies regarding human PGC induction from pluripotent cells have clarified a difference in expression of *Prdm14* between mice and humans during the transition from pluripotent cells to PGCs ([@bib13], [@bib29]). Interestingly, *PRDM14* is consistently expressed at moderate levels in pluripotent cells, i.e., primitive streak cells, which are precursors of PGCs in human, and PGCs, suggesting that PRDM14 is not a critical determinant for PGC specification in humans.

Here, we exploited adherent culture of EpiLCs in which *Prdm14* expression is controlled by doxycycline (Dox) to reveal the molecular and epigenetic function of PRDM14 during the transition from epiblast cells to PGCs in mice. We showed that inducing *Prdm14* expression in EpiLCs in adherent culture promotes pluripotency and self-renewal, resulting in conversion from EpiLCs to ESC-like cells (ESCLCs).

Results {#sec2}
=======

PRDM14 Overexpression Converts EpiLCs to ESC-like Cells {#sec2.1}
-------------------------------------------------------

*Prdm14* is expressed in proximal epiblast cells at around E6.5 that constitute PGC precursors in mice. In three-dimensional aggregate culture of EpiLCs, PRDM14 has been shown to be sufficient to induce PGCLCs ([@bib21]). To exclude the effect of cell-cell contact in three dimensions and investigate the direct function of PRDM14 in PGC development, we exploited adherent culture of EpiLCs, in which *Prdm14* expression was controlled by Dox treatment (ROSA-Tet-off \[[Figures 1](#fig1){ref-type="fig"} and [5](#fig5){ref-type="fig"}\] and piggyBac Tet-on \[[Figures 2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}, [4](#fig4){ref-type="fig"}, and [6](#fig6){ref-type="fig"}\]) ([Figures 1](#fig1){ref-type="fig"}A and 1B) ([@bib11]). ESCs were transferred onto fibronectin and stimulated with bFGF and activin A in N2B27 medium containing 1% KO serum replacement (KSR), and 2 days after EpiLC induction, *Prdm14* expression was induced by removal of Dox in Glasgow minimum essential medium containing 15% KSR (GK15), which is the basic medium used for PGCLC induction ([Figures 1](#fig1){ref-type="fig"}C and 1D) ([@bib23]). The morphology of EpiLCs expressing *Prdm14* changed from flattened to small, compact colonies, and the cells regained alkaline phosphatase (AP) activity to a degree similar to that of ESCs, which was associated with the reactivation of pluripotency genes ([Figures 1](#fig1){ref-type="fig"}E and 1F). Interestingly, the expression of early PGC markers in EpiLCs expressing PRDM14 was comparable with that in ESCs, and we were able to expand EpiLCs expressing PRDM14 at multiple passages, which clearly indicates that PRDM14 induction in EpiLCs does not induce PGCLCs ([Figure S1](#mmc1){ref-type="supplementary-material"}A). To evaluate the self-renewal capacity and pluripotency of *Prdm14*-expressing EpiLCs, we assessed colony formation along with AP activity in ESCs grown at low density under standard culture conditions (serum plus LIF). The number of AP-positive colonies was higher for EpiLCs overexpressing PRDM14 than for control EpiLCs ([Figure 1](#fig1){ref-type="fig"}G). Interestingly, despite the absence of LIF, we were able to expand PRDM14-expressing EpiLCs several times, and these cells retained expression of pluripotency genes except for *Klf4*, which is a direct target of LIF signaling ([Figure S1](#mmc1){ref-type="supplementary-material"}B). Moreover, the cells formed three germ layers in the subcutaneous region of nude mice, indicating that PRDM14 expression confers self-renewal capacity and pluripotency in EpiLCs independent of LIF signaling ([Figure 1](#fig1){ref-type="fig"}H).

To determine the transcriptional dynamics in PRDM14-expressing EpiLCs, we performed a microarray analysis using total RNA from ESCs, EpiLCs at day 2 (d2), EpiLCs + PRDM14, and EpiLCs (d4). Unsupervised hierarchical clustering revealed that the global gene expression profile of EpiLCs + PRDM14 was more similar to that of ESCs than that of EpiLCs ([Figure 2](#fig2){ref-type="fig"}A). Scatterplots of EpiLCs (d2) and EpiLCs + PRDM14 showed that 669 genes, including those associated with pluripotency, were upregulated, and 480 genes, including those encoding DNA methyltransferases or associated with differentiation, were downregulated by *Prdm14* expression in EpiLCs ([Figure 2](#fig2){ref-type="fig"}B). Unsupervised hierarchical clustering of genes up- or downregulated by PRDM14 in EpiLCs formed four clusters ([Figure 2](#fig2){ref-type="fig"}C). Genes in cluster 1 did not show a significant change in the transition from ESCs to EpiLCs, but were upregulated thereafter, whereas cluster-2 genes showed downregulation from ESCs to EpiLCs, followed by upregulation. Genes in cluster 3 showed relatively high expression from ESCs to EpiLCs followed by downregulation, whereas those in cluster 4 showed upregulation from ESCs to EpiLCs before subsequent downregulation. According to gene ontology (GO) functional annotations, stem cell maintenance (e.g., *Tcl1*, *Nanog*, *nuclear receptor subfamily* \[*Nr*\]*5a2*, and estrogen-related receptor β \[*Esrrb*\]), and DNA methylation (e.g., *Dnmt3a*/*b*) genes were enriched in clusters 2 and 4, respectively ([Figures 2](#fig2){ref-type="fig"}C and 2D). PRDM14 overexpression in epiblast stem cells (EpiSCs) partially activated pluripotency genes without inducing their conversion to ESCs, even in the presence of LIF ([@bib7]). To identify candidate genes regulated by PRDM14 that can account for the difference between EpiLC and EpiSC conversion to ESCs, we compared the top 1,000 probes that were differentially upregulated by PRDM14 overexpression in EpiLCs and EpiSCs according to published data ([@bib7]). Critical pluripotency factors such as *Tcl1*, *Nanog*, *Nr5a2*, transcription factor CP2-like 1 (*Tfcp2l1*), and *T-box 3* (*Tbx3*) were upregulated by PRDM14 in EpiLCs but not in EpiSCs ([Figure 2](#fig2){ref-type="fig"}E), suggesting that differences in the epigenetic landscape of pluripotency-associated genes between EpiLCs and EpiSCs may be critical for their activation by PRDM14. In the case of genes downregulated by PRDM14, epigenetic modifiers controlling DNA and H3K9 methylation---including *Dnmt3a*, *Dnmt3l*, *ubiquitin-like PHD* and *RING finger domain-containing protein 1* (*Uhrf1*), *helicase lymphoid-specific* (*Hells*), and *suppressor of variegation 3--9 homolog 1* (*Suv39h1*)---were downregulated by PRDM14 only in EpiLCs ([Figure S2](#mmc1){ref-type="supplementary-material"}A), which may be necessary for the establishment of an epigenetic background that ensures the conversion from EpiLCs to ESCLCs.

We used adherent EpiLC cultures to investigate the function of PRDM14 while excluding the effects of three-dimensional cell-cell contact. EpiLCs expressing PRDM14 could be expanded for long time periods, implying that EpiLCs were not induced to become PGCLCs under our culture conditions. In contrast, forced expression of PRDM14 in aggregate EpiLC cultures induced PGCLCs but not ESCLCs ([@bib21]). Germ cell specification consists of two major events: the acquisition of potential pluripotency (by reactivation of genes such as *Nanog*, *Klf2*, and *Tcl1*) and of germ cell character (by activation of *Blimp1*, *Nanos3*, and *dead-end protein homology 1*) ([@bib16], [@bib40]). The difference in cell fate between PRDM14-expressing EpiLCs grown as adherent or aggregate cultures suggests that acquisition of pluripotency is directly controlled by PRDM14, while three-dimensional cell-cell interactions between EpiLCs are required for the induction of germ cell characteristics, including the activation of germline-specific genes. A recent analysis of global gene expression in the differentiation of ESCs to EpiLCs and of EpiLCs to PGCLCs identified genes that were enriched in ESCs, EpiLCs, and d2 and d6 PGCLCs ([@bib17]). We compared the characteristics of EpiLCs expressing PRDM14 grown under our culture conditions with ESC highest genes, d6 PGCLCs, and EpiLC highest genes in a Venn diagram. The majority of transcription factors critical for ESC pluripotency among ESC highest genes were upregulated by PRDM14 in adherent EpiLC cultures, while genes most highly expressed in d6 PGCLCs were generally not upregulated by PRDM14 in these cultures including *Blimp1* (*Prdm1*), a critical determinant of germ cell specification ([@bib22]) ([Figures 2](#fig2){ref-type="fig"}F and 2G). These findings led us to speculate that a combination of *Prdm14* induction and three-dimensional cell-cell contact is necessary for the induction of *Blimp1* expression in EpiLCs. To clarify the response of EpiLCs to PRDM14 induction in aggregate culture and adherent culture, we established PRDM14-inducible ESCs carrying two reporters, *Blimp1-mVENUS* (BV) and *stella-eCFP* (SC) (BVSC), and monitored the fluorescence of mVENUS and eCFP in different culture conditions ([@bib11]). At 2 days after PRDM14 induction in EpiLCs at aggregate culture, the aggregates showed both BV and SC expression ([Figure 2](#fig2){ref-type="fig"}H), which provides evidence of PGCLC induction, as shown in a previous study ([@bib21]). By contrast, adherent-cultured EpiLCs expressing PRDM14 showed no BV expression and weak SC expression, which is consistent with the expression profile in ESCs ([@bib11]). *Blimp1* is upregulated by the mesoderm marker gene *T* (*Brachyury*) ([@bib1]). We therefore compared *T* expression levels in adherent and aggregate EpiLC cultures. Interestingly, *T* was only upregulated in EpiLC aggregate cultures both with and without *Prdm14* induction ([Figure 2](#fig2){ref-type="fig"}G), suggesting that three-dimensional cell-cell interactions are required for *T* expression, which induces PGCs along with PRDM14. A comparison of genes downregulated by PRDM14 in adherent EpiLC cultures with EpiLC highest genes showed that many EpiLC highest genes including *Otx2* and *Foxd3* ([@bib2], [@bib28]), which are known to important for the transition from naive to primed pluripotency, were repressed by PRDM14, indicating that PRDM14 suppresses epiblast characteristics ([Figure S2](#mmc1){ref-type="supplementary-material"}B).

*Klf2* Is Required for the Acquisition of Pluripotency by PRDM14 {#sec2.2}
----------------------------------------------------------------

Adherent culture of EpiLCs with PRDM14 is a powerful tool to uncover the molecular and epigenetic mechanisms for potential re-establishment of pluripotency by PRDM14, because this system induces the conversion from EpiLCs to ESCLCs at high efficiency and uniformly. We first focused on the function of KLF2, which is activated soon after induction of PRDM14 in EpiLCs in adherent culture. KLF2 has been shown to act synergistically with PRDM14 in the reversion of EpiSCs to ESCs ([@bib7]); the interaction between the two proteins in ESCs was confirmed by immunoprecipitation (IP) ([Figure 3](#fig3){ref-type="fig"}A). To clarify the role of *Klf2* in the PRDM14-associated acquisition of pluripotency, we generated *Klf2* KO ESCs harboring a Dox-inducible *Prdm14* expression cassette using the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system ([Figures 3](#fig3){ref-type="fig"}B and 3C). Interestingly, we did not observe AP-positive colonies in *Klf2*-null EpiLCs expressing PRDM14, which demonstrated that *Klf2* is essential for the PRDM14-induced conversion of EpiLCs to ESCLCs ([Figure 3](#fig3){ref-type="fig"}D and 3E). To clarify the cause of the loss of AP activity in EpiLCs + PRDM14 in *Klf2* KO, we compared the repression of differentiation markers and activation of pluripotency-associated markers by PRDM14 in wild-type (WT) and *Klf2* KO using qRT-PCR analysis. We plotted the relative Ct values of qRT-PCR data (EpiLCs + PRDM14 − EpiLCs \[d2\]) for WT (y axis) and *Klf2* KO (x axis). Consistent impairment of activation of pluripotent-associated genes by PRDM14 was observed, whereas the repression of differentiation markers by PRDM14 was relatively maintained in *Klf2* KO EpiLCs ([Figure 3](#fig3){ref-type="fig"}F). These results indicate that PRDM14 cooperates with KLF2 to convert EpiLCs to ESCLCs through the activation of pluripotency-associated genes.

PRDM14-Induced Acquisition of Pluripotency Occurs via TET-Dependent Active Demethylation {#sec2.3}
----------------------------------------------------------------------------------------

We previously showed that PRDM14 promotes active demethylation of pluripotency genes in ESCs via the TET-BER pathway ([@bib25]). To assess the role of the TET-BER pathway in PRDM14-induced acquisition of pluripotency, we established a *Tet1*/*Tet2* knockdown (KD) ESC line with a Dox-inducible *Prdm14* cassette ([Figure S3](#mmc1){ref-type="supplementary-material"}A). *Tet1*/*Tet2* KD prevented the reactivation of *Nanog*, *Klf2*, *Tcl1*, and *Esrrb* but not of *Sox2* and also prevented AP-positive colony formation by PRDM14 under ESC culture conditions ([Figures 4](#fig4){ref-type="fig"}A and 4B), while the repression of *Dnmt3b* and differentiation markers by PRDM14 occurred normally in *Tet1*/*Tet2* KD EpiLCs ([Figure S3](#mmc1){ref-type="supplementary-material"}B). CpG methylation level at PRDM14 binding regions of *Nanog* and *Tcl1* in ESCs substantially increased in the transition from ESCs to EpiLCs; these marks were rapidly removed by *Prdm14* induction ([Figure 4](#fig4){ref-type="fig"}C). In contrast, the removal of 5-methylcytosine (5mC) by PRDM14 at *Nanog* and *Tcl1* loci was impaired by *Tet1*/*Tet2* KD. Furthermore, treatment of EpiLCs expressing PRDM14 with pharmacological inhibitors of the BER components DNA endonuclease apurinic/apyrimidinic endonuclease (3-aminobenzamide) and poly(ADP-ribose) polymerase (CRT 004876) abrogated the reversion of EpiLCs to ESCLCs, similar to the *Tet1*/*Tet2* KD phenotype ([Figures 4](#fig4){ref-type="fig"}D and 4E). To investigate the role of TET proteins in global gene expression profiles regulated by PRDM14 in EpiLCs, we compared genes that were up- or downregulated by PRDM14 in WT and *Tet1*/*Tet2* KD EpiLCs by microarray analysis. Genes that were up- or downregulated by PRDM14 in WT EpiLCs showed corresponding up- and downregulation in *Tet1*/*Tet2* KD EpiLCs ([Figure S4](#mmc1){ref-type="supplementary-material"}A). These genes were of four types: ESC-, PGC-, or EpiLC-enriched, or epigenetic modifiers. We examined the effect of *Tet1*/*Tet2* KD on the transcriptional regulation of these genes by PRDM14 in EpiLCs ([Figure S4](#mmc1){ref-type="supplementary-material"}B). The expression of PGC- and EpiLC-enriched genes and epigenetic modifiers was unaltered by PRDM14 in *Tet1*/*Tet2* KD EpiLCs. In contrast, activation of ESC-enriched genes by PRDM14 was impaired in *Tet1*/*Tet2* KD EpiLCs. We observed, however, that ESC-enriched genes tended to be upregulated by PRDM14 even in *Tet1*/*Tet2* KD EpiLCs, suggesting that TET proteins cooperate with an unknown pathway regulated by PRDM14 to activate ESC-enriched genes in EpiLCs ([Figure S4](#mmc1){ref-type="supplementary-material"}B).

PRDM14 Enhances OCT3/4 Binding to *Klf2* Enhancers via the TET-BER Pathway {#sec2.4}
--------------------------------------------------------------------------

Because *Klf2* activation is critical for acquisition of pluripotency by PRDM14, we investigated the molecular and epigenetic mechanisms of *Klf2* activation by PRDM14. Both PRDM14 and OCT3/4 bind to proximal and distal enhancers of the *Klf2* locus in ESCs ([Figure 5](#fig5){ref-type="fig"}A) ([@bib10], [@bib18]). We therefore evaluated the binding of PRDM14 and OCT3/4 to the *Klf2* locus in the transition from ESCs to EpiLCs and dedifferentiation of EpiLCs to ESCLCs by chromatin IP (ChIP)-qPCR. Since ChIP-grade anti-PRDM14 antibody was unavailable, we detected the binding of exogenous FLAG-PRDM14 in EpiLCs using an anti-FLAG antibody ([Figure 5](#fig5){ref-type="fig"}B). After *Prdm14* expression was induced in EpiLCs, two distinct peaks appeared at the proximal and distal enhancers of *Klf2* ([Figure 5](#fig5){ref-type="fig"}B). Under our culture conditions, OCT3/4 was present only at distal enhancers of *Klf2*, and this peak disappeared in the transition from ESCs to EpiLCs ([Figure 5](#fig5){ref-type="fig"}B). Interestingly, induction of *Prdm14* expression enhanced the binding of OCT3/4 at both proximal and distal enhancers of *Klf2* in EpiLCs.

We next measured 5mC and 5hmC levels at two enhancers of *Klf2* in ESCs, EpiLCs, and EpiLCs + PRDM14. In ESCs, 5mC was detected only at proximal enhancers of *Klf2*, which was correlated with absence of OCT3/4 at the proximal enhancer ([Figures 5](#fig5){ref-type="fig"}B and 5C). At the distal enhancer of *Klf2*, 5mC level was transiently upregulated during the differentiation of ESCs to EpiLCs; this was followed by a downregulation induced by PRDM14. In contrast, the 5hmC level remained constant. To determine the temporal hierarchy of events (PRDM14 and OCT3/4 binding, 5mC removal, and activation of *Klf2* expression), we analyzed *Prdm14* and *Klf2* expression as well as PRDM14 and OCT3/4 binding, and 5mC and 5hmC distribution at the two *Klf2* enhancers every 6 hr after *Prdm14* induction in EpiLCs. *Prdm14* expression was detected starting 18 hr after induction; this was followed by increased PRDM14 binding at the two enhancers at 24 hr ([Figures 5](#fig5){ref-type="fig"}D, [S5](#mmc1){ref-type="supplementary-material"}A, and S5B). In contrast, OCT3/4 binding at these sites first appeared 42 hr after *Prdm14* induction ([Figures 5](#fig5){ref-type="fig"}D and [S5](#mmc1){ref-type="supplementary-material"}B). PRDM14 was found to interact with TET1 and TET2 but not with OCT3/4 in EpiLCs ([Figure 5](#fig5){ref-type="fig"}E), suggesting that PRDM14 indirectly enhances OCT3/4 recruitment to these enhancers. Interestingly, the level of 5mC rapidly reduced while that of 5hmC increased after PRDM14 recruitment to these enhancers ([Figures 5](#fig5){ref-type="fig"}F and [S5](#mmc1){ref-type="supplementary-material"}C). To determine whether active demethylation by PRDM14 is required for OCT3/4 binding, we examined the effects of BER inhibitor (BERi) on 5mC removal from and OCT3/4 recruitment to these enhancers. BERi treatment completely disrupted the rapid removal of 5mC by PRDM14 at both *Klf2* enhancers in EpiLCs ([Figures 5](#fig5){ref-type="fig"}G and [S5](#mmc1){ref-type="supplementary-material"}D). Under these conditions, OCT3/4 recruitment was abrogated although PRDM14 enrichment was unaltered ([Figures 5](#fig5){ref-type="fig"}H and [S5](#mmc1){ref-type="supplementary-material"}E). Taken together, these data indicate that PRDM14 activates *Klf2* expression via active demethylation-mediated recruitment of OCT3/4 to the enhancers ([Figure S5](#mmc1){ref-type="supplementary-material"}F).

To identify the genomic regions at which PRDM14 enhances OCT3/4 recruitment, we performed ChIP for OCT3/4 and PRDM14 (α-FLAG) followed by deep sequencing (ChIP-seq) in ESCs, EpiLCs, and EpiLCs expressing PRDM14, and identified 18,093, 8,136, and 13,882 OCT3/4 peaks, respectively, using the MACS2 callpeak ([@bib5]). Next, to investigate the effects of PRDM14 on OCT3/4 binding, we compared the enrichment of OCT3/4 peaks among ESCs, EpiLCs, and EpiLCs expressing PRDM14 by using the MACS2 bdgdiff module ([@bib5]). Over half of the OCT3/4 binding in ESCs was reduced and only 312 peaks increased in the transition of ESCs to EpiLCs ([Figure 6](#fig6){ref-type="fig"}A); 2 days after PRDM14 induction, 2,542 OCT3/4 binding peaks increased or had appeared, and those corresponding to 1,559 genes colocalized with PRDM14 binding peaks ([Figure 6](#fig6){ref-type="fig"}B). Approximately 6.3% (98 of 1,559) of genes in which OCT3/4 binding was enhanced by PRDM14 were upregulated by PRDM14, whereas approximately 2.8% (43 of 1,559) of genes in which OCT3/4 binding was upregulated by PRDM14 were downregulated by *Prdm14* induction in EpiLCs ([Figure 6](#fig6){ref-type="fig"}B). An overrepresentation analysis using DAVID ([@bib12]) revealed that GO terms related to stem cell maintenance, including *Tcl1*, *Nr5a2*, and *Tfcp2l1*, were enriched among the upregulated genes ([Figures 6](#fig6){ref-type="fig"}C and 6D). Consistent with ChIP-seq data, the enrichment of OCT3/4 binding at five of the genes decreased during differentiation of ESC to EpiLC, with a consequent increase in OCT3/4 binding peaks by PRDM14 binding-associated induction ([Figure 6](#fig6){ref-type="fig"}E). To determine whether PRDM14-mediated DNA demethylation modulates the recruitment of OCT3/4 to the five genes, we measured 5mC and 5hmC levels at the binding regions of OCT3/4 and PRDM14 by glucosylation of genomic DNA followed by methylation-sensitive (GlucMS)-qPCR ([Figure 6](#fig6){ref-type="fig"}F). 5mC levels were elevated at all genes analyzed during ESC-to-EpiLC differentiation, whereas at three of the five genes the levels decreased after PRDM14 induction in EpiLCs. These findings indicate that PRDM14 acts via DNA demethylation-dependent and -independent mechanisms to recruit OCT3/4.

Discussion {#sec3}
==========

This study provides evidence that PRDM14 confers pluripotency and self-renewal capacity to EpiLCs by reactivating pluripotency genes via TET-BER-mediated active demethylation ([Figure 7](#fig7){ref-type="fig"}). Nascent PGCs reactivate pluripotent-associated genes during specification from epiblast cells. Our data suggest that the activation of PRDM14 in epiblast is a key event for reactivation of pluripotent-associated genes and the acquisition of potential pluripotency. Our data demonstrate that EpiLC culture conditions (i.e., adherent versus aggregate) determine the expression of two key genes for PGC specification, *T* and *Blimp1* ([@bib22]) ([Figures 2](#fig2){ref-type="fig"}G and 2H). Moreover, adherent EpiLC cultures with *Prdm14* induction resulted in the conversion of EpiLCs to ESCLCs, whereas three-dimensional aggregate cultures induced PGCLCs ([@bib21]). It has been shown that the WNT3-β-catenin axis induces *T* expression in epiblast culture in aggregate culture of EpiLCs ([@bib1]). Therefore, we consider that aggregate culture of EpiLCs enhance WNT3-β-catenin signaling to activate *T* expression. Further experiments are needed to clarify whether the combination of PRDM14 with BLIMP1 or T can induce PGCLCs from EpiLCs in adherent culture.

*Tet1*/*Tet2* KD and BERi treatment impaired the reactivation of pluripotency genes by PRDM14, reducing the conversion efficiency of EpiLCs to ESCLCs. However, the reactivation of pluripotency genes by PRDM14 was partially inhibited by *Tet1*/*Tet2* KD and BERi treatment, implying that PRDM14 acts via a TET-BER-independent mechanism in this process. Furthermore, PRDM14-induced activation of PGC-enriched genes including *Tfap2c*, developmental pluripotency-associated 3 (*Dppa3*), and reproductive homeobox 6/9 (*Rhox6*/*9*) was normal in *Tet1*/*Tet2* KD EpiLCs. These data are consistent with the phenotype of *Tet1*/*Tet2* double KO (DKO) PGCs, and demonstrate normal PGC specification and development ([@bib41]). Further studies examining the developmental potential of EGCs derived from *Tet1*/*Tet2* DKO PGCs are needed to clarify the function of TET1/TET2 in the acquisition of pluripotency by PGCs in vivo.

The concordance between ChIP-seq and microarray data provided evidence that PRDM14 recruits OCT3/4 to enhancer regions of pluripotency genes, leading to their transcription during the conversion from EpiLCs to ESCLCs. The 5mC marks at *Nr5a2*, *Tfcp2l1*, and *Tfap2c* enhancers were removed by PRDM14 in EpiLCs, while 5mC at replication timing regulatory factor 1 (*Rif1*) and spalt-like transcription factor 4 (*Sall4*) enhancers were unchanged. Interestingly, the reactivation of *Rif1* and *Sall4* by PRDM14 was impaired in *Tet1*/*Tet2* double KD EpiLCs ([Figure S4](#mmc1){ref-type="supplementary-material"}B). These results suggest that TET proteins are involved in the reactivation of *Rif1* and *Sall4* by PRDM14 via DNA demethylation-independent mechanisms. In support of this possibility, TET proteins were required for the recruitment of O-linked N-acetylglucosamine (O-GlcNAc) transferase to target chromatin, which leads to its activation via O-GlucNAcylation of histone H2B ([@bib3], [@bib36]).

Recently, various groups have independently succeeded in inducing human PGCLCs from human pluripotent stem cells (PSCs) ([@bib13], [@bib29], [@bib34]). For instance, human PGCLCs were more robustly induced from mesoderm-like cells (iMeLCs) and human ESCs cultured in medium containing four inhibitors, called "4i" medium; they expressed some mesoderm markers. Although most naive pluripotency genes are repressed in the transition from ESCs to EpiLCs in mice, most genes including *KLF2*, *TCL1A*, *ESRRB*, *TFCP2L1*, and nuclear receptor subfamily 0 B1 (*NR0B1*) showed low expression in human ESCs/induced PSCs (iPSCs). Although expression of *Prdm14* is closely associated with naive pluripotency in mice, primed human ESCs/iPSCs, primitive streak-like cells, iMeLCs, and 4i ESCs consistently express PRDM14 at moderate levels. Therefore, the specific upregulation of *Prdm14* observed during the transition from pluripotent cells to PGCs in mice does not occur in human PGC specification. The present study has clearly demonstrated that PRDM14 governs the transcriptional network for pluripotency in the absence of BLIMP1 in mice. In contrast to early mouse embryos, epiblast cells in human early embryos need to maintain pluripotency for longer than 10 days until the emergence of PGCs. Furthermore, primitive streak-like cells, which have a high capacity for PGC specification, retain pluripotency markers including NANOG and PRDM14 ([@bib13], [@bib29]). On this basis, we hypothesize that continuous expression of PRDM14 is essential for the long-term maintenance of pluripotent cells to give rise to PGCs in humans. In contrast to our hypothesis, it has also been shown that PRDM14 KD ESCs are competent for PGCLC induction, which led to the conclusion that PRDM14 is not necessary for PGC induction in humans ([@bib34]). However, another group has clearly shown that *PRDM14* KD induces human ESC differentiation ([@bib4]), implying that the KD efficiency in the study of [@bib34] was quite low and that conclusions cannot be drawn regarding the role of PRDM14 in human PGC development. Therefore, additional KO studies are needed to clarify the molecular and epigenetic functions of PRDM14 in the human germline.

The conversion of EpiLCs to ESCLCs is similar to the late stage of somatic cell reprogramming, since activation of pluripotency genes by PRDM14 is associated with DNA demethylation of their promoters. Given these findings, we consider that PRDM14-dependent active demethylation of pluripotency genes is required for progression of the late stage of somatic cell reprogramming. This is supported by the fact that *Prdm14* KO fibroblasts failed to be converted to iPSCs in the absence of *Nanog* and *Sox2* reactivation under standard ESC culture conditions ([@bib26]). Furthermore, epigenetic errors result in partially reprogrammed iPSCs and low-grade iPSCs ([@bib33], [@bib35]). Our findings provide a framework for understanding not only physiological but also artificial (e.g., iPSC derivation) and pathological (e.g., the appearance of cancer stem cells) reprogramming.

Experimental Procedures {#sec4}
=======================

Cell Culture {#sec4.1}
------------

E14tg2a ESCs were cultured in Glasgow minimum essential medium (Wako) containing 10% fetal calf serum (Invitrogen), 1 mM glutamine (Wako), nonessential amino acid (Wako), and 0.1 mM 2-mercaptoethanol (Wako). The culture was supplemented with LIF (Wako) in the absence of feeder cells.

Teratoma Formation and Histological Analysis {#sec4.2}
--------------------------------------------

Approximately 5 × 10^6^ EpiLCs expressing PRDM14, cultured without LIF, were injected subcutaneously into both the flanks of female nude mice. After 30 days, the tumors were excised, embedded in paraffin, and sectioned into 4-μm-thick slices. H&E staining was done according to the standard protocol. Markers for the three germ layers were monitored with immunofluorescence with antibodies: α-AFP (Proteintech; 14550-1-AP), α-SMA (Abcam; ab5694), and α-β-tubulin (Cell Signaling; catalog no. 2146). These experiments were conducted according to the Kwansei Gakuin University Regulation for Animal experimentation.

Generation of *Prdm14*-Inducible ESCs by ROSA-Tet-Off and piggyBac Tet-On {#sec4.3}
-------------------------------------------------------------------------

For the ROSA-Tet-off system, EBRTcH3 cells were transfected with pZhc-Prdm14 and pCAGGS-Cre ([@bib19]). For the Tet-on system, E14tg2a ESCs and BVSC ESCs ([@bib11]) were transfected with PB-TET-FLAG-*Prdm14*-IRES-Neo, PB-CA-rtTA Adv, pCAG-Pbase, and pGG131 (pCAG-DsRed-IRES-Hygro). The cells were grown in selective medium containing 1.5 μg/mL puromycin (Sigma-Aldrich) and 200 μg/mL hygromycin B (Wako) for 7 days ([@bib25]). Colonies were picked and analyzed by qRT-PCR and western blotting to determine PRDM14 expression levels, with and without doxycycline.

RNAi {#sec4.4}
----

*Tet1* and *Tet2* small hairpin RNAs (shRNAs) were generated from pLKO.1-puro (Addgene; 8453) or pLKO.1-blast (Addgene; 26655). The *Tet1* and *Tet2* shRNAs were adapted for pLKO.1 plasmids. The RNAi target sequences are presented in [Table S1](#mmc2){ref-type="supplementary-material"}. pLKO.1 lentiviruses were constructed according to the Addgene pLKO.1 protocol (<http://www.addgene.org/>). pLKO.1 plasmids were co-transfected with pCMV-VSV-G (Addgene; 8454) and pCMV-dR8.2 dvpr (Addgene; 8455) into HEK293T cells. Lentivirus-containing supernatants were centrifuge-filtered through a 0.45-μm filter. Clarified supernatants were combined using the Lenti-X Concentrator (Clontech) according to the manufacturer\'s protocol. The mixture was centrifuged, after which the supernatant was carefully removed and the pellet resuspended in DMEM.

For lentivirus transduction, subconfluent iP14 ESCs were incubated with lentivirus-containing DMEM supplemented with 8 μg/mL polybrene (Sigma-Aldrich) for 24 hr. After changing the spent medium with fresh medium, cells were selected with 2 μg/mL puromycin (Sigma-Aldrich) or 20 μg/mL blasticidin S hydrochloride (Calbiochem). Knockdown efficiency was analyzed by qRT-PCR and western blotting.

Generation of *Klf2*-Knockout ESCs Using a CRISPR/Cas9 System {#sec4.5}
-------------------------------------------------------------

*Klf2* guide RNA was adapted for and generated from the pX330-U6-Chimeric_BB-CBh-hSpCas9 plasmid (Addgene; 42230). The *Klf2* guide RNA sequences are presented in [Table S1](#mmc2){ref-type="supplementary-material"}. The established plasmid was co-transfected with pCAG-IRES-Puro into the induced PRDM14 ESCs, and the transfected cells were selected with 2 μg/mL puromycin. KLF2 expression was analyzed by western blot.

Induction of EpiLCs {#sec4.6}
-------------------

ESCs were cultured in N2B27 basal medium containing 3 μM CHIR99021 (Wako), 0.4 μM PD0325901 (Wako), and LIF in a dish coated with 0.01% poly-L-ornithine (Millipore) and 10 ng/mL laminin (BD Biosciences). Induction of EpiLCs was performed as described previously ([@bib11]). EpiLCs were induced from ESCs in N2B27 basal medium containing 20 ng/mL activin A (Peprotech), 12 ng/mL bFGF (Invitrogen), and 0.1--1% KSR for 2 days on a dish coated with 16.7 μg/mL human plasma fibronectin (Millipore). Two days after EpiLC induction, the cells were collected and replated (0.5--1.0 × 10^5^) with or without doxycycline in GK15 medium on a dish coated with 16.7 μg/mL human plasma fibronectin. For the colony formation assay for AP-positive cells, ESCs, EpiLCs, and EpiLCs induced with or without PRDM14 were dissociated by TrypLE Select (Invitrogen). Cells (1.0 × 10^4^) were cultured under standard ESC culture conditions. After culture for 3 days, the cells were stained for AP activity. The aggregate culture of EpiLCs was performed as previously reported ([@bib21]). In brief, after 36 hr of EpiLC induction the cells were collected, and 2,000 cells per well were transferred to a low-cell binding 96-well plate (NUNC). The cells were grown for 2 days in GK15 medium with or without 1.5 μg/mL doxycycline.

qRT-PCR {#sec4.7}
-------

Total RNA was extracted using TRIzol (Invitrogen). The ReverTra Ace qPCR RT kit (Toyobo) was used for cDNA synthesis according to the manufacturer\'s instructions. Subsequently, cDNA was used as a template for qPCR with the Thunderbird SYBR qPCR Mix (Toyobo) and gene-specific primers ([Table S1](#mmc2){ref-type="supplementary-material"}) on a LightCycler 96 system (Roche).

Western Blot and Immunoprecipitation Analysis {#sec4.8}
---------------------------------------------

Cells were lysed by boiling in SDS sample buffer (Wako). The total proteins from lysed cells were denatured by 2-mercaptoethanol and were then applied to polyacrylamide-SDS gels. The proteins were separated on polyacrylamide-SDS gels, blotted on polyvinylidene fluoride membrane, and probed using the following primary antibodies: α-PRDM14 (R & D Systems; MAB8097), α-tubulin (Sigma; T5168), α-histone H3 (Abcam; ab1791), α-FLAG (Sigma; F1804), α-KLF2 (Millipore; 09--820), α-TET1 (Millipore; 09--872), α-TET2 (Santa Cruz Biotechnology; sc-136926), and α-OCT3/4 (Santa Cruz; sc-8628). Following the primary antibody reaction, the membrane was incubated with secondary horseradish peroxidase-coupled antibodies. Detection was achieved using the Luminata Forte Western HRP Substrate (Millipore). For immunoprecipitation analysis, extracts containing a protease inhibitor cocktail (Roche) were incubated with anti-PRDM14 antibody or anti-OCT3/4 antibody for 2 hr at 4°C, and captured with protein A beads. Protein complexes were washed with wash buffer (50 mM Tris-HCl \[pH 8.0\], 150 mM NaCl, 1% NP-40), and eluted by boiling with SDS sample buffer.
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![PRDM14 Induces the Transition of EpiLCs to ESCLCs\
(A) Constructs of the ROSA-Tet-off system and piggyBac Tet-on system.\
(B) Western blotting of PRDM14 and tubulin.\
(C) Scheme of the transition of ESCs to EpiLCs and of EpiLCs to ESCLCs.\
(D) qRT-PCR analysis of *Prdm14* expression in ESCs, EpiLCs (d2), EpiLCs (d4), and EpiLCs + PRDM14. Error bars indicate ±SD of a biological triplicate.\
(E) AP staining of ESCs, EpiLCs (d2), EpiLCs (d4), and EpiLCs + PRDM14. Scale bar, 50 μm.\
(F) qRT-PCR analysis of pluripotency genes in ESCs, EpiLCs (d2), EpiLCs (d4), and EpiLCs + PRDM14. Error bars indicate ±SD of a biological triplicate.\
(G) Colony formation by ESCs, EpiLCs (d4), and EpiLCs + PRDM14 was assessed by AP staining over 3 days in the presence of serum + LIF. Error bars indicate ±SD of biological triplicates. p Values were calculated with the Student\'s t test. Scale bar, 200 μm.\
(H) (Left) Teratoma formation by EpiLCs expressing *Prdm14* cultured in the absence of LIF. (Right) Immunofluorescent staining of α-fetoprotein (AFP), smooth muscle actin (SMA), and class III β-tubulin (TUJ1) in teratoma sections. Scale bar, 200 μm.\
^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, Student\'s t test.](gr1){#fig1}

![Global Gene Expression Profiles in the Transition from EpiLCs to ESCLCs\
(A) Unsupervised hierarchical cluster analysis of ESCs, EpiLCs (d2), EpiLCs (d4), and EpiLCs + PRDM14.\
(B) Scatter plots comparing the transcriptomes of EpiLCs + PRDM14 and EpiLCs (d2).\
(C) Heatmap visualization of data obtained by unsupervised hierarchical cluster analysis of genes up- and downregulated by PRDM14 in EpiLCs.\
(D) GO term overrepresentation analysis using DAVID.\
(E) Comparison of genes upregulated by PRDM14 in EpiLCs versus EpiSCs.\
(F) Comparison of genes upregulated by PRDM14 and those most highly expressed in ESCs and d6 PGCLCs ([@bib17]).\
(G) qRT-PCR analysis of pluripotency and germ cell-related genes in EpiLCs, and EpiLCs expressing PRDM14 and grown as adherent or aggregate cultures. Error bars indicate ±SD of a biological triplicate. ^∗^p \< 0.05, ^∗∗^p \< 0.01, Student\'s t test.\
(H) Comparison of the expression of PGC markers, Blimp1 (mVENUS) and stella (eCFP), between adherent culture and aggregate culture of EpiLCs with PRDM14. Scale bar, 200 μm.](gr2){#fig2}

![*Klf2* Is Required for the PRDM14-Induced Reversion of EpiLCs to ESCLCs\
(A) Immunoprecipitation of PRDM14 with KLF2 in ESCs.\
(B) Western blot analysis of KLF2 expression in WT and *Klf2* KO ESCs.\
(C) qRT-PCR analysis of *Prdm14* expression in WT and *Klf2* KO ESCs. Error bars indicate ±SD of a biological triplicate.\
(D) Colony formation by EpiLCs with or without *Prdm14* induction induced from WT or *Klf2* KO ESCs, as assessed by AP staining. Scale bar, 200 μm.\
(E) Quantification of colony formation shown in (D). Error bars indicate ±SD of biological triplicates. p Values were calculated with Student\'s t test.\
(F) Scatter plot shows relative Ct values of pluripotency-associated genes (red dots) and differentiation markers (blue dots) determined by qRT-PCR. The x axis indicates relative Ct values of each gene (EpiLCs + PRDM14 − EpiLCs \[d2\]) in WT, and the y axis indicates relative Ct values of each gene (EpiLCs + PRDM14 − EpiLCs \[d2\]) in *Klf2* KO.](gr3){#fig3}

![Reversion from Primed to Naive Pluripotency Induced by PRDM14 via the TET-BER Pathway\
(A) qRT-PCR analysis of *Prdm14* and pluripotency genes in ESCs, EpiLCs (d2), EpiLCs (d4), and EpiLCs + PRDM14 in WT and *Tet1*/*2* KD backgrounds. Error bars indicate ±SD of a biological triplicate. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, Student\'s t test.\
(B) Colony formation by EpiLCs with or without *Prdm14* induction induced from WT and *Tet1*/*2* KD ESCs, as determined by AP staining. Scale bar, 200 μm. Error bars indicate ±SD of biological triplicates. p Values were calculated with Student\'s t test.\
(C) Glucosylation of genomic DNA followed by methylation-sensitive (GlucMS)-qPCR analysis showing the percentage of 5mC and 5hmC marks in or near PRDM14 binding regions of the *Nanog* and *Tcl1* enhancers in ESCs, EpiLCs (d2), EpiLCs (d4), and EpiLCs + PRDM14 in WT and *Tet1*/*2* KD backgrounds. Error bars indicate ±SD of a biological triplicate.\
(D) qRT-PCR analysis of *Prdm14*, pluripotency genes, and *Fgf5* in ESCs, EpiLCs (d2), EpiLCs (d4), and EpiLCs + PRDM14 treated with DMSO (control), 3-aminobenzamide (3AB), and CRT 004876 (CRT). Error bars indicate ±SD of a biological triplicate. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, Student\'s t test.\
(E) Colony formation by EpiLCs + PRDM14 treated with DMSO, 3AB, and CRT as assessed by AP staining. Error bars indicate ±SD of a biological triplicate. p Values were calculated with Student\'s t test. Scale bar, 200 μm.](gr4){#fig4}

![PRDM14 Increases OCT3/4 Recruitment to *Klf2* via the TET-BER Pathway\
(A) Schematic representation of ChIP data for PRDM14 and OCT3/4 at the *Klf2* locus in ESCs ([@bib10], [@bib18]) and PRDM14 and OCT3/4 recognition motifs at two enhancers.\
(B) ChIP-qPCR analysis of PRDM14 (α-FLAG) and OCT3/4 at the *Klf2* locus in ESCs, EpiLCs (d2), and EpiLCs + PRDM14. Fold enrichment was calculated by comparing pre-immune immunoglobulin G (IgG) control (red dotted line) with each antibody. Error bars indicate ±SD of a technical duplicate.\
(C) GlucMS-qPCR analysis showing the percentage of 5mC and 5hmC marks at two *Klf2* enhancers in ESCs, EpiLCs (d2), and EpiLCs + PRDM14. Error bars indicate ±SD of a technical duplicate.\
(D) ChIP-qPCR analysis of PRDM14 (α-FLAG) and OCT3/4 at the *Klf2* locus every 6 hr after *Prdm14* induction. Error bars indicate ±SD of a technical duplicate.\
(E) Western blot (WB) analysis of FLAG, OCT3/4, TET1, and TET2 levels following immunoprecipitation (IP) of EpiLCs + PRDM14 precipitated with an anti-FLAG antibody.\
(F) GlucMS-qPCR analysis of the percentage of 5mC and 5hmC marks at the *Klf2* locus every 6 hr after *Prdm14* induction. Error bars indicate ±SD of a technical duplicate.\
(G) GlucMS-qPCR showing the percentage of 5mC and 5hmC marks at the *Klf2* locus in EpiLCs + PRDM14 treated with DMSO(DMSO; control), 3-aminobenzamide (3AB), or CRT 004876 (CRT). Error bars indicate ±SD of a technical duplicate.\
(H) ChIP-qPCR analysis of PRDM14 (α- FLAG) and OCT3/4 at the *Klf2* locus in EpiLCs + PRDM14 treated with DMSO, 3AB, or CRT. Fold enrichment was calculated by comparing pre-immune IgG control (red dotted line) with each antibody. Error bars indicate +SD of a technical duplicate.](gr5){#fig5}

![Enhancement of OCT3/4 Binding by PRDM14 during Reversion from Primed to Naive Pluripotency\
(A) Comparison of OCT3/4 binding peaks between ESCs and EpiLCs (d2), EpiLCs (d2) and EpiLCs + PRDM14, and EpiLCs + PRDM14 and ESCs. Numbers in gray rectangles indicate peaks common to both cell types in each pair. Numbers in blue, red, and green rectangles indicate peaks specific to ESCs, EpiLCs (d2), and EpiLCs + PRDM14, respectively.\
(B) Genes downregulated by PRDM14 during the transition from EpiLCs to ESCLCs (red circles). Genes associated with PRDM14 and OCT3/4 binding that were enhanced during the transition of EpiLCs to ESCs are indicated by navy circles; genes upregulated by PRDM14 in EpiLCs are shown by yellow circles.\
(C) GO annotation of genes upregulated by PRDM14 in which OCT3/4 binding increased with PRDM14 binding (from EpiLCs to EpiLCs + PRDM14).\
(D) ChIP-seq tracks of OCT3/4 and PRDM14 in ESCs, EpiLCs (d2), and EpiLCs + PRDM14. Intensity values of microarray data are shown on the right side. Red bar indicates the position of the primers for ChIP-qPCR and GlucMS-qPCR.\
(E) ChIP-qPCR analysis of OCT3/4 and PRDM14 expression in ESCs, EpiLCs (d2), and EpiLCs + PRDM14. Fold enrichment indicates values of each IgG relative to input values using the same amount of DNA as template. Error bars indicate ±SD of a technical duplicate.\
(F) GlucMS-qPCR analysis of the percentage of 5mC and 5hmC marks at pluripotency genes. Error bars indicate ±SD of a technical duplicate.](gr6){#fig6}

![Working Model of the Role of PRDM14 in the Conversion of EpiLCs to ESCLCs and PGC Specification](gr7){#fig7}
